Valuation dashboard for Petros Pharmaceuticals, Inc. (PTPI) with P/E 0.00, P/B 0.33, EV/EBITDA N/A and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
Balance sheet quality for PTPI: current ratio of 2.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 0.00 |
| Price / Book | 0.33 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.02 |
| vs Current Price | +228.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PTPI | Petros Pharmaceuticals, Inc. | 0.00 | 0.33 | ||
| TAK | Takeda Pharmaceutical Company Limited | $59.3B | 50.64 | 1.20 | 2.4% |
| TEVA | Teva Pharmaceutical Industries Limited | $44.9B | 58.46 | 5.53 | 9.2% |
| HLN | Haleon plc | $40.6B | 18.74 | 1.85 | 9.9% |
| 0M3Q.L | Zoetis Inc. | $35.4B | |||
| ZTS | Zoetis Inc. | $30.6B | 11.99 | 9.67 | 69.3% |
| HLN.L | Haleon plc | $29.9B | 20.08 | 2.08 | 10.1% |
| 0SAN.L | Sandoz Group AG | $28.3B | 52.81 | 3.84 | 7.0% |
Price
| Price | $0.01 |
| Market Cap | $0M |
| Exchange | OTC |
| Country | US |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CCM · CELU · HEPA · IVF · LIXT · PETV · PKBO
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of PTPI: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks